New hope for brain cancer patients in groundbreaking UK drug trial
NCT ID NCT06630260
Summary
This UK trial is testing new oral drug combinations for aggressive brain tumors like glioblastoma. It aims to see if the drugs avutometinib and defactinib, given alone or with a standard chemotherapy, are safe and can help control tumor growth. The study will enroll 182 patients whose tumors have specific genetic markers, first testing in people whose cancer has returned, then potentially in newly diagnosed patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University Hospitals
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital - Drug Development Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital - Neuro-Oncology Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.